TABLE 2.
Time (min) | Mixed meal |
Glimepiride |
||
---|---|---|---|---|
Placebo | Diazoxide | Placebo | Diazoxide | |
Heart rate (bpm) | ||||
−60 | 69 ± 4 | 71 ± 2 | 70 ± 4 | 71 ± 3 |
−30 | 70 ± 3 | 70 ± 3 | 72 ± 4 | 70 ± 3 |
0 | 73 ± 4 | 77 ± 3 | 69 ± 4 | 70 ± 4 |
30 | 79 ± 5 | 86 ± 4 | 68 ± 4 | 73 ± 4 |
60 | 78 ± 5 | 81 ± 4 | 67 ± 5 | 78 ± 4 |
90 | 77 ± 4 | 84 ± 4 | 68 ± 4 | 74 ± 3 |
120 | 77 ± 6 | 85 ± 4 | 69 ± 5 | 77 ± 4 |
150 | 76 ± 5 | 80 ± 4 | 70 ± 4 | 77 ± 4 |
180 | 74 ± 5 | 81 ± 4 | 75 ± 4 | 84 ± 4 |
(P < 0.0001) | (P < 0.0001) | |||
Systolic blood pressure (mmHg) | ||||
−60 | 118 ± 2 | 121 ± 3 | 118 ± 2 | 118 ± 3 |
−30 | 116 ± 3 | 121 ± 3 | 122 ± 2 | 126 ± 3 |
0 | 120 ± 3 | 121 ± 3 | 122 ± 2 | 118 ± 2 |
30 | 118 ± 3 | 118 ± 3 | 119 ± 2 | 118 ± 2 |
60 | 119 ± 3 | 117 ± 3 | 120 ± 2 | 118 ± 2 |
90 | 116 ± 3 | 117 ± 3 | 119 ± 2 | 115 ± 3 |
120 | 116 ± 3 | 114 ± 2 | 122 ± 3 | 114 ± 2 |
150 | 115 ± 3 | 112 ± 3 | 119 ± 3 | 115 ± 3 |
180 | 118 ± 3 | 113 ± 3 | 122 ± 3 | 114 ± 3 |
(P = 0.2173) | (P < 0.0001) | |||
Diastolic blood pressure (mmHg) | ||||
−60 | 65 ± 2 | 68 ± 2 | 69 ± 2 | 68 ± 2 |
−30 | 66 ± 2 | 69 ± 2 | 68 ± 1 | 73 ± 3 |
0 | 65 ± 3 | 67 ± 2 | 66 ± 2 | 68 ± 2 |
30 | 61 ± 3 | 58 ± 2 | 65 ± 2 | 66 ± 2 |
60 | 60 ± 2 | 59 ± 3 | 68 ± 2 | 61 ± 3 |
90 | 58 ± 2 | 60 ± 2 | 65 ± 2 | 60 ± 3 |
120 | 62 ± 2 | 57 ± 2 | 66 ± 2 | 60 ± 2 |
150 | 63 ± 2 | 58 ± 3 | 68 ± 2 | 59 ± 3 |
180 | 62 ± 2 | 57 ± 2 | 66 ± 2 | 60 ± 3 |
(P = 0.0339) | (P < 0.0001) |
*Mean ± SE data are shown after oral administration of placebo or diazoxide (6.0 mg/kg) at −30 min and a mixed meal (Ensure Plus) at 0 min on two occasions (left) or oral glimepiride (4.0 mg) on another two occasions (right) in healthy humans.